Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

AAV-AQP1

Generic Name: AAV-AQP1

Drug Type: Biotech

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction

Phase 1

Active, not recruiting

Posted: 2015/05/18

Sponsor:MeiraGTx, LLC

ID:NCT02446249

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

MeiraGTx and Hologen AI Form $430 Million Strategic Collaboration to Advance Parkinson's Disease Gene Therapy

2 months ago

MeiraGTx has secured a strategic collaboration with Hologen AI that includes a $200 million upfront payment and the formation of a joint venture with an additional $230 million in committed capital to advance AAV-GAD gene therapy for Parkinson's disease.

MeiraGTx's AAV2-hAQP1 Receives FDA RMAT Designation for Radiation-Induced Xerostomia

6 months ago

MeiraGTx's AAV2-hAQP1 gene therapy has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for grade 2/3 radiation-induced xerostomia (RIX).

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy